ALK and non-small cell lung carcinoma: With regard to the combination of ICIs and targeted therapies, a number of studies had evaluated the combiantion of ALK TKIs and different ICIs in NSCLC, including the combination of nivolumab with ceritinib or crizotinib and the combiantion of alectinib plus atezolizumab (105–107).